[Urinary excretion of alpha-glucosidase in various kidney diseases].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to L Campanacci.
Explore the source record for details and available documents.
The plasma kinetics of some antibiotics (pivampicillin, cephaloridine, streptomycin) has been studied in patients with chronic renal failure. The oral administration of pivampicllin promptly increases the plasma levels of the antibiotic, without any toxic side effect: this antibiotic is to be chosen in chronic uremic patients, also during regular dialytic treatment (R.D.T.). Cephaloridine has some renal toxic effects in high concentration; in the renal failure it is advisable to calculate the exact dose of the antibiotic by the use of nomograms when the creatinine clearance is known. These nomograms must absolutely be employed when administrating some toxic antibiotics, as gentamycin and streptomycin in chronic uremic patients. Some formulas have been experimentally determined, which allow a calculation of the exact dose of the antibiotic, also during R.D.T. If a kidney or urinary tract infection is present in patients with low G.F.R. (creatinine-clearance less than 30 ml/min.), it is necessary to administer only those antibiotics which can reach an active urinary concentration (i.e. penicillin and derivatives, cephaloridine).
Explore the source record for details and available documents.
Plasma lipidic fractions (total lipids, free and total cholesterol, triglycerides, total phospholipids and low density lipoproteins) of 16 hyperlipemic subjects have been followed up over a 4-week period. Intravenous injection of exogenous phospholipids prepared from pig heart resulted in a significant decrease of all the examined lipidic fractions. The possible mechanims of exogenous phospholipids action is discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.